Key Trends and Insights into the Empagliflozin, Dapagliflozin And Canagliflozin Market: Growth Rate and Opportunities to 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Future CAGR is Anticipated for the Empagliflozin, Dapagliflozin And Canagliflozin Market Over the 2025–2034 Period?
The market size for empagliflozin, dapagliflozin and canagliflozin has seen consistent growth in the past few years. It is projected to expand from $9.64 billion in 2024 to $9.94 billion in 2025, showcasing a compound annual growth rate (CAGR) of 3.1%. The substantial growth during the previous period was due to the global rise in type 2 diabetes cases, heightened awareness of the advantages of SGLT2 inhibitors, surge in the elderly demographic, increase in obesity cases, and an intensified emphasis on personalized medicine.
The market for empagliflozin, dapagliflozin and canagliflozin is predicted to experience consistent growth in the coming years, swelling to a value of $11.06 billion in 2029, reflecting a compound annual growth rate (CAGR) of 2.7%. Factors contributing to growth in this market during the forecast period include a rising demand for oral diabetes medication, an increase in investments towards diabetes research and medication development, amplified healthcare spend, heightening awareness and diagnosis of pre-diabetes conditions, and a growing emphasis on combination therapies. The forecast period is also expected to see trends such as technological innovation, combination therapies, telehealth, health data analytics, and patient data privacy.
Which Factors Are Enhancing the Growth of the Empagliflozin, Dapagliflozin And Canagliflozin Market?
The growth of the empagliflozin, dapagliflozin, and canagliflozin market is predicted to be driven by the escalating prevalence of diabetes. This persistent health challenge is characterized by heightened blood sugar levels, arising from either insufficient insulin production or the body’s inability to use insulin effectively. The rise in diabetes can be linked to factors like inactive lifestyles, unhealthy eating patterns, genetic tendencies, city living, and aging population, further complicated by a lack of access to health services and increasing global obesity rates. Empagliflozin, dapagliflozin, and canagliflozin are employed to control diabetes by reducing blood sugar levels. They work by blocking sodium-glucose co-transporter-2 (SGLT2) in the kidneys, thereby encouraging glucose discharge through urine. For instance, statistics from the UK’s National Health Service (NHS) in June 2024 indicate a troubling rise in diabetes in individuals under 40; numbers grew from 173,166 in 2022 to 216,440 in 2023, highlighting the alarming growth in this demographic. This data reveals a swift increase in diabetes occurrences among younger age groups. Thus, the escalating prevalence of diabetes is fueling the growth of the empagliflozin, dapagliflozin, and canagliflozin market.
Request Your Free Empagliflozin, Dapagliflozin And Canagliflozin Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=18350&type=smp
Who Are the Influential Players Fueling Innovation and Growth in the Empagliflozin, Dapagliflozin And Canagliflozin Market?
Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are:
• Fujifilm_x000D_
• Stryker Corporation_x000D_
• Boston Scientific Corporation_x000D_
• B. Braun Melsungen AG_x000D_
• Olympus Corporation_x000D_
What Impact Are Industry Trends Having on the Empagliflozin, Dapagliflozin And Canagliflozin Market’s Future Prospects?
Leading enterprises in the segments of empagliflozin, dapagliflozin, and canagliflozin are targeting the formulation of novel products such as treatments for type-2 diabetes in children. This is to accommodate a more diverse patient group and increase their influence in the sphere of diabetes care. The regimen for pediatric type-2 diabetes consists of controlling blood sugar levels through alterations in lifestyle, prescription drugs, and occasionally, insulin therapies customized for young people. For example, AstraZeneca – a pharmaceutical organization based in the UK, outlined in June 2024 that the US FDA endorsed Farxiga (dapagliflozin) to enhance glycemic management in pediatric patients aged 10 or more with type-2 diabetes. The sanction is founded on the positive results obtained from the T2NOW Phase III clinical trial, arguably one of the most comprehensive trials dedicated to pediatric type-2 diabetes so far, which indicated that Farxiga prominently lowered HbA1c levels compared to placebo. The safety record of Farxiga in this patient category was in line with the results observed in adult type-2 diabetes patients. This endorsement represents a significant development since oral remedies for pediatric type-2 diabetes were previously scarce, furthermore, it highlights AstraZeneca’s commitment to bringing forward creative solutions in the treatment of cardiovascular, renal, and metabolic diseases.
Pre-order Your Report for Quick and Easy Delivery!
Which Segments Play a Crucial Role in the Expansion of the Empagliflozin, Dapagliflozin And Canagliflozin Market?
The empagliflozin, dapagliflozin and canagliflozin market covered in this report is segmented –
1) By Type: Empagliflozin, Dapagliflozin, Canagliflozin
2) By Application: Application I, Application II, Application III, Application IV
3) By Channel: Hospital, Pharmacy
Subsegments:
1) Empagliflozin: 10 Mg, 25 Mg, 50 Mg
2) Dapagliflozin: 5 Mg, 10 Mg
3) Canagliflozin: 100 Mg, 300 Mg
What Regions Are Leading the Growth Trajectory of the Empagliflozin, Dapagliflozin And Canagliflozin Market?
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2024. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Defining Aspects of the Empagliflozin, Dapagliflozin And Canagliflozin Market Landscape?
Empagliflozin, dapagliflozin, and canagliflozin are medications classified as sodium-glucose co-transporter-2 (SGLT-2) inhibitors primarily used in treating type 2 diabetes mellitus. These medications are taken orally and are part of a broader diabetes management plan that includes diet, exercise, and other medications as needed.
Browse Through More Similar Reports By The Business Research Company:
Wireless Internet Services Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/wireless-internet-services-global-market-report
Broadband Internet Services Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/broadband-internet-services-global-market-report
Commercial And Service Industry Machinery Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
